Owens Corning — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Owens Corning filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $7.16B | Feb 19, 2020 |
| FY2019 | Dec 31, 2018 | $7.06B | Feb 19, 2020 |
| FY2019 | Dec 31, 2017 | $6.38B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $5.68B | Feb 20, 2019 |
| FY2017 | Dec 31, 2015 | $5.35B | Feb 21, 2018 |
| FY2016 | Dec 31, 2014 | $5.26B | Feb 8, 2017 |
| FY2015 | Dec 31, 2013 | $5.30B | Feb 10, 2016 |
| FY2014 | Dec 31, 2012 | $5.17B | Feb 11, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.10B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $9.85B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $8.37B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $9.76B | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $8.50B | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $7.06B | Feb 15, 2023 |
| FY2019 | Dec 31, 2019 | $1.69B | Feb 19, 2020 |
| FY2019 | Sep 30, 2019 | $1.88B | Feb 19, 2020 |
| FY2019 | Jun 30, 2019 | $1.92B | Feb 19, 2020 |
| FY2019 | Mar 31, 2019 | $1.67B | Feb 19, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.84B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $3.04B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $2.43B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $2.62B | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $2.22B | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $1.61B | Feb 15, 2023 |
| FY2019 | Dec 31, 2019 | $383.00M | Feb 19, 2020 |
| FY2019 | Sep 30, 2019 | $461.00M | Feb 19, 2020 |
| FY2019 | Jun 30, 2019 | $440.00M | Feb 19, 2020 |
| FY2019 | Mar 31, 2019 | $325.00M | Feb 19, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($522.00M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $647.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.20B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $1.24B | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $995.00M | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | ($383.00M) | Feb 15, 2023 |
| FY2019 | Dec 31, 2019 | $73.00M | Feb 19, 2020 |
| FY2019 | Sep 30, 2019 | $150.00M | Feb 19, 2020 |
| FY2019 | Jun 30, 2019 | $138.00M | Feb 19, 2020 |
| FY2019 | Mar 31, 2019 | $44.00M | Feb 19, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $360.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.48B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.64B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $1.71B | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $1.44B | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | ($138.00M) | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $787.00M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $807.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $797.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $697.00M | Feb 20, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $150.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $131.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $110.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $106.00M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $91.00M | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $82.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $87.00M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $89.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $85.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $82.00M | Feb 20, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.01B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $959.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $748.00M | Feb 25, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.79B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.89B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.72B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $1.76B | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $1.50B | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $1.14B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $1.04B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $803.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $1.02B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $943.00M | Feb 20, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.98B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $14.08B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $11.24B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $10.75B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $10.02B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $9.48B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $10.01B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $9.77B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $8.63B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $7.74B | Feb 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.09B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $8.96B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $6.03B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $6.13B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $5.68B | Feb 15, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.85B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $5.08B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $5.17B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $4.58B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $4.30B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $3.90B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $4.63B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $4.28B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $4.16B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $3.85B | Feb 21, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.68B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $2.75B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.39B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.38B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $990.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $989.00M | Feb 16, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.46B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $5.22B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $4.79B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $3.79B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $2.71B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.83B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $2.32B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $2.01B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $1.58B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $1.38B | Feb 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $345.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $321.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.62B | Feb 24, 2025 |
| FY2024 | Dec 31, 2022 | $1.10B | Feb 24, 2025 |
| FY2022 | Dec 31, 2021 | $959.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $717.00M | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $172.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $78.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $246.00M | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $112.00M | Feb 21, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.12B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $5.10B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $3.05B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $3.02B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $2.99B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $3.15B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $2.99B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $3.37B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $2.41B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $2.10B | Feb 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 7 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 13 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 12 | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | 9 | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 15, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 19, 2020 |
| FY2019 | Sep 30, 2019 | 1 | Feb 19, 2020 |
| FY2019 | Jun 30, 2019 | 1 | Feb 19, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 19, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 7 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 13 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 12 | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | 9 | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | (3) | Feb 15, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 19, 2020 |
| FY2019 | Sep 30, 2019 | 1 | Feb 19, 2020 |
| FY2019 | Jun 30, 2019 | 1 | Feb 19, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 19, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 80.20M | Feb 25, 2026 |
| FY2024 | Dec 31, 2024 | 85.40M | Feb 24, 2025 |
| FY2024 | Dec 31, 2023 | 87.20M | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | 91.90M | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | 100.40M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | 105.60M | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | 109.50M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | 109.50M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | 111.50M | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | 112.70M | Feb 21, 2018 |